Ann: Investor Presentation, page-572

You:
"Looking specifically at seeing how IL2Ralpha inhibition was correlated with changes in T cells activation in patients blood 28 days after treatment - we'll they could only do that if the patients blood was taken and recording allowing them to do that - and that only occurred in the case of 25 patients."

I don't believe that statement is correct:
"Results: Biomarker data were collected in 40 subjects. At baseline, the mean age was 8.5 years, aGVHD severity by IBMTR grade C or D, median MAP was 0.369, with a MAP ≥ 0.291 in 60% of subjects, reflecting active gastrointestinal inflammation and high risk for 6-month NRM."
https://ash.confex.com/ash/2020/webprogram/Paper140899.html

25 patients or as I understood the 60% of the 40 patients (24, but 62.5% seemed close enough to me) of these subjects with a MAP ≥ 0.291, were then matched with "27 closely matched children from the Mount Sinai Acute GVHD International Consortium (MAGIC)2 who participated in a prospective natural history study" to show the survival benefit of the patient group treated with remestemcel-L vs SoC.
https://www.globenewswire.com/news-release/2021/10/18/2315632/0/en/Remestemcel-L-Improves-Survival-of-Children-With-Biomarkers-for-Highest-Mortality-in-Steroid-Refractory-Acute-GVHD.html

Or is the above simply coincidence (genuine question)?